{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:04:45Z","timestamp":1784948685648,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":2380,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:p>Dapoxetine is being developed as a treatment for premature ejaculation and has demonstrated rapid absorption and elimination in previous pharmacokinetic studies. Two open\u2010label studies were conducted in healthy men: a parallel\u2010group pharmacokinetic and safety study in young and elderly men and a randomized crossover food\u2010effect study. Maximal plasma dapoxetine concentrations (C<jats:sub><jats:italic>max<\/jats:italic><\/jats:sub>) were similar in young and elderly men (338 and 310 ng\/mL, respectively), as were the corresponding area under the plasma concentration versus time curve (AUC) values (2040 and 2280 ng\u00b7h\/mL, respectively). When coadministered with food, C<jats:sub><jats:italic>max<\/jats:italic><\/jats:sub> was reduced by 11% (398 vs 443 ng\/mL in the fed and fasted states, respectively), and the peak was delayed by approximately 30 minutes, indicating that food slowed the rate of absorption; however, systemic exposure to dapoxetine (ie, AUC) was not affected by food consumption. Thus, age or consumption of a high\u2010fat meal has only a modest impact on dapoxetine pharmacokinetics in healthy men.<\/jats:p>","DOI":"10.1177\/0091270006291033","type":"journal-article","created":{"date-parts":[[2006,8,18]],"date-time":"2006-08-18T17:53:12Z","timestamp":1155923592000},"page":"1023-1029","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacokinetics of Dapoxetine, a New Treatment for Premature Ejaculation: Impact of Age and Effects of a High\u2010Fat Meal"],"prefix":"10.1002","volume":"46","author":[{"given":"Mark J.","family":"Dresser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwoo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mulhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishit B.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.20353.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/00926230390224738"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/00926239708403932"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000132159.61156.ea"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0022-5347(18)35972-X","article-title":"Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation","volume":"173","author":"Pryor JL","year":"2005","journal-title":"J Urol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00048-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005284850"},{"key":"e_1_2_6_9_2","volume-title":"Celexa (citalopram hydrobromide) [package insert]","year":"2005"},{"key":"e_1_2_6_10_2","volume-title":"PAXIL (paroxetine hydrochloride) [package insert]","year":"2005"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.6.537"},{"key":"e_1_2_6_12_2","unstructured":"ShabsighR PerelmanMAMen with both premature ejaculation (PE) and erectile dysfunction (ED) experience lower quality of life than men with either PE or ED alone. Presented at: The XVII World Congress of Sexology; July 10\u201315 2005; Montreal Canada."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00003"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1989.tb07185.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199700321-00008"},{"key":"e_1_2_6_16_2","first-page":"503","article-title":"Pharmacokinetics of second generation antidepressants: fluoxetine","volume":"27","author":"Goodnick PJ","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_17_2","unstructured":"US Food and Drug Administration.Center for Drug Evaluation and Research. Guidance for Industry: Food\u2010Effect Bioavailability and Fed Bioequivalence Studies.December 2002. Available at:http:\/\/www.fda.gov\/cder\/guidance\/5194fnl.pdf. Accessed July 19 2005."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01068419"},{"key":"e_1_2_6_20_2","first-page":"70","volume-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow S","year":"1992"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199019020-00001"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733040-00005"},{"key":"e_1_2_6_23_2","volume-title":"PROZAC (fluoxetine hydrochloride) [package insert]","year":"2005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nu.16.070196.002123"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270006291033","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270006291033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T04:38:20Z","timestamp":1697517500000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270006291033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1177\/0091270006291033"],"URL":"https:\/\/doi.org\/10.1177\/0091270006291033","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}